Member Info for andinio

There's a far greater story here:
Yesterday we knew Orph was developing a challenge model with a hope of approval.
Today we know UK Gov wants to be on-board. Process to end-game timed, primed with needed confirmation that Orph are not pushing against a headwind.
It's going to be much easier to achieve MHRA approval with UK Gov as your partner/customer.

RNS content inline with my expectations.
Confirmation of article and UK Gov funding. Excellent.
Further news to come.

Open Orphan is mentioned.

The project’s academic leader is Imperial College London, and it will be run by hVivo, a spinout from Queen Mary University of London that was bought earlier this year by Open Orphan, a Dublin-based pharmaceutical research organisation.

and this....

The FT report said 1Day Sooner is launching a campaign this week to get public funding for a biocontainment facility for the studies, big enough to quarantine 100 to 200 volunteers.

Finger first, raise glass second.

Buys printing @ 17p
Remember this moment.

...there's your sensational news for September.
Anyone care about H1 results now? ;)

Open Orphan in firework mode :)
https://twitter.com/OpenOrphan/status/1308397908350431235

Yep, it appears more bouyant towards a preferred range.
I'm hoping CF will counter H1 results with strong forward guidance.

Agreed.
Still opportunities before post-H1 results newsflow for bargains.

Extract:
In theory, the sale of genetic data does not have to be a one-off either, but something that can be repeated, with the same windfall on each occasion. Taking the 450,000 cohort which Genuity has aimed for, at a price of $1,500 per sample, you’re left with a databank with a value of $675m with the possibility of resales.

Referencing a DNA sample:
"A recent presentation by pharmaceutical research company Open Orphan put the price per sample at anything between $450 and $3,000. A compromise figure of $1,500 is often accepted as the current going rate.
Apply that rate to a full population and you begin to see that genomics is big business, with large-scale pharma multinationals on the lookout for areas where they can access swathes of genetic data, ostensibly for pharmaceutical research, most especially in the field of rare disease drugs.
Individual citizens owning the rights to their own genetic data is far from usual, but that cannot alter the fact that the acquisition of such data is big business in 2020."

The data is of significant value [financially] regardless of how it's monetized.
What's very clear, we're now very close to seeing the data work for the Co through wearables or other means.

Thumbs up.
Great opening question.

Moniman.
To claim Deepjoy was 'negative' is to oversimplify his comments.
He was - in part - critical while remaining constructive.
'Constructive' being a key element.

LB
Hilarious.

According to CF we can expect news supporting quarantine unit fully booked for 18 months to 2 yrs.
I'd like to see that RNS :)

Registration:
https://www.sharesmagazine.co.uk/events

The train arrived at the station and we boarded the train.
The staff are being extremely courteous to us yet the train remains at the platform.
Happy to remain seated but it's hot outside and the collar's feeling tight around the neckline.
The buffet car is open but they're serving the same menu as last week, and the week before.
You know the feeling.
All that frustration goes away when you feel that sudden jolt as the engine car engages drive with the carriages.
What we don't want is the announcement "the train leaving platform one is cancelled". :)

Yes, i noticed.
Considered trade.
I wonder what may be coming in our direction next.
Autumn 2020 :)